Condition: Castration-Resistant Prostate Cancer (CRPC) · Colorectal Cancer · NSCLC (Non-small Cell Lung Cancer) · Sponsor: Radiopharm Theranostics, Ltd
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This description comes directly from the study's public registry record.
Dimitris Voliotis, MD · 646-535-5017 · dv@radiopharmtheranostics.com
Always discuss trial participation with your own doctor first.
| Dothan Hematology & Oncology | Dothan, Alabama, United States | Recruiting |
| BAMF Health | Grand Rapids, Michigan, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| XCancer | Omaha, Nebraska, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07189871